Spiriva Respimat 2.5 µg inhal. sol. cartr. Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

spiriva respimat 2.5 µg inhal. sol. cartr.

boehringer ingelheim international gmbh - tiotropium bromide monohydrate 3,124 µg/dose - eq. tiotropium 2,5 µg/dose - inhalation solution - 2,5 mcg - tiotropium bromide monohydrate - tiotropium bromide

Srivasso 18 µg inhal. pwdr. (hard caps.) Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

srivasso 18 µg inhal. pwdr. (hard caps.)

boehringer ingelheim international gmbh - tiotropium bromide monohydrate 22,5 µg - eq. tiotropium 18 µg - inhalation powder, hard capsule - 18 µg - tiotropium bromide monohydrate 22.5 µg - tiotropium bromide

Tiotropium Viatris 18 µg inhal. pwdr. (hard caps.) Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

tiotropium viatris 18 µg inhal. pwdr. (hard caps.)

viatris gx bv-srl - tiotropium bromide 21,67 µg - eq. tiotropium 18 µg - inhalation powder, hard capsule - 18 µg - tiotropium bromide 21.67 µg - tiotropium bromide

Sirkava 18 microgram, inhalation powder, hard capsule Malta - angļu - Medicines Authority

sirkava 18 microgram, inhalation powder, hard capsule

mylan ireland limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - tiotropium bromide - inhalation powder hard capsule - tiotropium bromide 18 µg - drugs for obstructive airway diseases

SPIRIVA RESPIMAT Izraēla - angļu - Ministry of Health

spiriva respimat

boehringer ingelheim israel ltd. - tiotropium bromide as monohydrate - solution for inhalation - tiotropium bromide as monohydrate 2.5 mcg - tiotropium bromide - maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (copd).copd:tiotropium is indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (copd).asthma:spiriva respimat is indicated as add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year.